COMMUNIQUÉS West-GlobeNewswire

GBT Announces New Employment Inducement Grants
06/03/2019
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2019, the compensation committee of GBT’s board of directors granted [...]
Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
06/03/2019
- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with ipilimumab and with [...]
Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2019
06/03/2019
OTTAWA, March 06, 2019 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) reported today its unaudited financial results for Q1 2019. For the three-month period ended January 31, 2019, the [...]
Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team
06/03/2019
Dr. Aurelia De Pauw to Oversee Clinical Operations ORLEANS, Ontario, March 06, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (" Tetra " or the " Corporation ") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in [...]
ViroGates announces launch of suPARnostic® TurbiLatex for the Roche cobas c 502 module
06/03/2019
Company announcement no. 1-2019 Birkerød, 6 March 2019 ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that it has [...]
Zealand Pharma doses first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism
06/03/2019
Press Release – No. 05/2019 Zealand Pharma doses first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism Congenital hyperinsulinism (CHI) is a rare pediatric disease with high [...]
Oasmia Pharmaceutical Strengthens its Management Team and Organization
06/03/2019
To increase resources and its business development function, Oasmia has employed Anette Sjödin as Executive Vice President to focus on commercialization and business development. The organization is further strengthened [...]
LIDDS: Final patient enrolled in Phase IIb Liproca® Depot prostate cancer study
06/03/2019
The last patient has been enrolled in LIDDS Phase IIb study for the localized treatment of prostate cancer. The Phase IIb study will identify the optimal dose for Phase III and test the safety of Liproca ® Depot and its [...]
Recording of the Fourth Quarter 2018 Investor Conference Webinar
06/03/2019
On March 5 JSC Olainfarm organized its Investor Conference - Online Webinar. During the webinar the Advisor to the Board of JSC Olainfarm Salvis Lapiņš analyzed the financial results of fourth quarter and 12 months of [...]
Nicox : Résultats financiers 2018 et étapes clés en 2019
06/03/2019
Communiqué de presse Nicox : Résultats financiers 2018 et étapes clés en 2019 ................................................. Augmentation de 74% du chiffre d'affaires net 1 Réduction de la perte avant impôt en 2018 [...]
Nicox Announces 2018 Financial Results and 2019 Milestones
06/03/2019
Press Release Nicox Announces 2018 Financial Results and 2019 Milestones ................................................ Net revenue 1 increased by 74% Loss before tax in 2018 reduced compared to 2017 Cash balance and [...]
ERYTECH to Host Fourth Quarter and Full Year 2018 Conference Call and Business Update
06/03/2019
LYON, France, March 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug [...]
ERYTECH tiendra un webcast le 12 mars 2019 à l’occasion de ses résultats annuels 2018
06/03/2019
LYON, France, 06 mars 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris et Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les [...]
Akcea et Ionis obtiennent un avis positif du CHMP de l'UE concernant WAYLIVRA™ (volanesorsen)
06/03/2019
Premier et unique traitement approuvé pour le FCS, une maladie grave et rare pour laquelle aucun traitement n’est approuvé BOSTON, Massachusetts et CARLSBAD, Californie, 06 mars 2019 (GLOBE NEWSWIRE) -- Akcea [...]
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
06/03/2019
COPENHAGEN, Denmark, March 05, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon TM technology to address unmet medical needs, today announced [...]
Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock
06/03/2019
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public [...]
REVA Announces Extension to Voluntary Suspension of Trading
06/03/2019
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 6 March 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating [...]
MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan
06/03/2019
LA JOLLA, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
WW – the new Weight Watchers – Announces Participation in Upcoming Investor Conferences
06/03/2019
NEW YORK, March 05, 2019 (GLOBE NEWSWIRE) -- Weight Watchers International, Inc. (Nasdaq: WTW) (“WW”), a global wellness company and the world’s leading commercial weight management program, today announced that Mindy [...]

Pages